brain metastases

brain metastases

A generic term for cancer which has spread from a primary tumour, most commonly small cell carcinoma, of the lung to the brain.

brain metastases

Oncology Cancer that has spread from a primary tumor, most commonly, small cell carcinoma of the lung, to the brain
Mentioned in ?
References in periodicals archive ?
Puma Biotechnology Inc (NASDAQ: PBYI) announced the FDA granted Orphan Drug Designation to its Nerlynx for the treatment of breast cancer patients with brain metastases.
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
Food and Drug Administration , FDA, has granted Orphan Drug Designation to NERLYNX, neratinib, for the treatment of breast cancer patients with brain metastases. "Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to developing treatments for patients with HER2-positive breast cancer," said Alan H.
FDA grants Puma Biotechnology's Nerlynx for breast cancer treatment
These conjugates include xB3-001, Bioasis' lead product conjugate with trastuzumab in development for the treatment of HER2+ breast cancer brain metastases. The allowed claims of this patent application also cover pharmaceutical compositions containing the conjugates.
Bioasis Announces Registration and Grant Notice of Patent Application in China Relating to xB3 Platform Technology
The trial, which opened for enrollment in the fall of 2018 and whose lead clinical investigator is Jana Portnow, M.D., city of Hope associate clinical professor in the Department of Medical Oncology and Therapeutics Research, is testing the safety and effectiveness of the CAR T cell therapy for breast cancer patients with brain metastases who are not effectively being controlled with other therapies.
City of Hope Scientist Receives USD 9.28m for CAR T Cell Immunotherapy Clinical Trial for Patients With HER2-Positive Breast Cancer That Has Spread to the Brain
Approximately 25% of patients with EGFRm NSCLC have brain metastases at diagnosis, increasing to approximately 40% within two years of diagnosis.6 The presence of brain metastases often reduces median survival to less than eight months.7
Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer
The Investigational New Drug (IND) application of Phase II/III clinical trial for breast cancer carcinoma brain metastases (BCBS) in China has been approved by the National Medical Products Administration (NMPA).
Innovent Biologics Inc partners with Shenogen Pharma Group Ltd for advanced cancer
The researchers likewise found that the nano-vaccine can be used to treat melanoma brain metastases. 
Melanoma Nano-Vaccine Effective Against Skin Cancer In Animal Study
Lapatinib has been shown to prevent the development of brain metastases in breast cancer when combined or alone.
Lapatinib? or Radiotherapy? In Cranial Metastasis of Breast Cancer
The researchers linked data on brain metastases to investigate rates of brain metastasis in elderly patients.
Elderly cancer survivors face risk of brain metastasis: Study
Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS).
Tumour Treating Fields (TTFs) for Paediatric Brain Tumours, Brain Metastases and other Novel Applications
Brain metastases (BM) from NSCLC are poor prognosis, with a median survival of 6 months following whole-brain radiotherapy.
The clinical outcome of brain metastases in nonsmall cell lung cancer patients with epidermal growth factor receptor mutation- A retrospective single-institution analysis

Medical browser ?
Full browser ?